NCT03401671View on ClinicalTrials.gov

Study of Lanadelumab in Healthy Japanese and Matched Caucasian Adult Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

January 15, 2018

Primary Completion Date

May 30, 2018

Study Completion Date

May 30, 2018

Conditions
Healthy Volunteers
Interventions
DRUG

Lanadelumab

SC injection of 300mg in 2mL (150 mg/mL) solution of lanadelumab will be administered as a single dose injection in the abdomen.

Trial Locations (1)

90630

WCCT Global, Inc., Cypress

Sponsors

Lead Sponsor

Shire
All Listed Sponsors
lead

Shire

INDUSTRY

NCT03401671 - Study of Lanadelumab in Healthy Japanese and Matched Caucasian Adult Subjects | Biotech Hunter | Biotech Hunter